Investigator's global assessment (IGA) of improvement Treatment 'success' as defined by IGA score decrease5 · Moderate and severe acne vulgaris
ALA‐PDT showed no clear difference in investigator's global assessment (IGA) of improvement Treatment… compared with blue light only (low certainty).
1 finding from 1 review
Lesion count · Mild, moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed severe adverse effects Blistering or scarring · Mild, moderate and severe acne vulgaris
1 finding from 1 review
Paticipant's global assessment of improvement ‐ Not measured · Moderate and severe acne vulgaris
The review found no eligible studies for this question.
1 finding from 1 review
Light therapies for acne 2016 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Investigator‐assessed change in inflamed lesions (ILs) Lesion counts · Moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed change in non‐inflamed lesions (NILs) Lesion counts · Moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed percentage change in ILs Lesion counts · Moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed percentage change in NILs Lesion counts · Moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed severe adverse effects Application site blister · Moderate and severe acne vulgaris
1 finding from 1 review
Participant‐ or parent‐reported global assessment of disease severity · adults and children with atopic eczema and inhalant allergen sensitisation
1 finding from 1 review
Participant‐ or parent‐reported specific symptoms of eczema · adults and children with atopic eczema and inhalant allergen sensitisation
1 finding from 1 review
Any systemic reactions during therapy · adults and children with atopic eczema and inhalant allergen sensitisation
Specific allergen immunotherapy showed no clear difference in adverse events ‐ any systemic reaction compared with no immunotherapy (moderate certainty).
1 finding from 1 review
Investigator‐ or physician‐rated global assessment of disease severity · adults and children with atopic eczema and inhalant allergen sensitisation
It is very uncertain whether specific allergen immunotherapy changes investigator‐ or physician‐rated global assessment of disease severity compared with no immunotherapy (very low certainty).
1 finding from 1 review
Investigator‐ or physician‐rated eczema severity using a published scale · adults and children with atopic eczema and inhalant allergen sensitisation
1 finding from 1 review
Participant or parent‐rated eczema severity using a published scale · adults and children with atopic eczema and inhalant allergen sensitisation
1 finding from 1 review
Number of participants achieving 'clearance' by IGA · scalp psoriasis
Steroid probably leads to higher number of participants achieving 'clearance' by IGA compared with vitamin D (moderate certainty).
1 finding from 1 review
Number of participants achieving 'response' by PGA · scalp psoriasis
Steroid plus vitamin D leads to higher number of participants achieving 'response' by PGA compared with steroid (high certainty).
1 finding from 1 review
Number of participants achieving 'clearance' by IGA · scalp psoriasis
Steroid plus vitamin D leads to higher number of participants achieving 'clearance' by IGA compared with vitamin D (high certainty).
1 finding from 1 review
Number of participants achieving 'response' by IGA · scalp psoriasis
Steroid plus vitamin D probably leads to higher number of participants achieving 'response' by IGA compared with vitamin D (moderate certainty).
1 finding from 1 review
Quality of life · scalp psoriasis
1 finding from 1 review